New Parkinson's drug candidate enters first safety tests in china

NCT ID NCT07513441

Not yet recruiting Disease control Sponsor: H. Lundbeck A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test the safety and tolerability of a new oral drug called Lu AF28996 in 10 Chinese adults with Parkinson's disease. Participants will take the drug and be monitored for side effects and how the body processes it. The study is not yet recruiting and does not aim to measure whether the drug improves symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lu AF28996 (oral capsule)
What this could lead to: If successful, this could lead to a new treatment option to help control Parkinson's symptoms.
What could go wrong: This is a very early, small study (10 people) focused only on safety and drug levels, not on effectiveness. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tiantan Hospital, Capital Medical University

Beijing, 100070, China
Huashan Hospital, Fudan University

Shanghai, 200040, China
West China Hospital, Sichuan University

Chengdu, 610041, China
Xuanwu Hospital Capital Medical University

Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.